Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pomalidomide + R-ICE
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pomalidomide + R-ICE is an investigational combination regimen consisting of pomalidomide, an immunomodulatory small molecule, added to the established R-ICE chemotherapy protocol (rituximab, ifosfamide, carboplatin, and etoposide). This combination is being studied as a salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have failed first-line treatment. Pomalidomide acts by modulating the immune system and exerting direct antineoplastic effects through multiple mechanisms including degradation of transcription factors Ikaros and Aiolos. The addition of pomalidomide to R-ICE aims to improve complete response rates compared to standard R-ICE alone[1]. The regimen is currently under investigation in phase I/II clinical trials.
- Other names
- PR-ICE
02
Targets
Beyond the preview
Go deeper on pomalidomide + R-ICE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pomalidomide + R-ICE.